CRISPR Therapeutics' Zugo-cel Shows Clinical Response in 5 of 6 Systemic Sclerosis Patients Receiving Standard Lymphodepletion

Bitget2026/11/08 15:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CRISPR Therapeutics reported encouraging preliminary results for investigational CAR-T therapy zugo-cel in a Phase 1 trial targeting refractory autoimmune diseases.
Systemic sclerosis results already presented at ACR Convergence 2026 showed most patients receiving standard lymphodepletion responded; all responders maintained improvement.
All nine inflammatory myopathy patients improved; two of three evaluable lupus patients maintained drug-free remission through at least nine months.
Zugo-cel was well tolerated across 21 patients as of October 15, 2026, with no dose-limiting toxicities or deaths reported.
Dose escalation remains ongoing across the rheumatology trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081030PRIMZONEFULLFEED9872813) on November 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CRISPR Therapeutics' Zugo-cel Shows Clinical Response in 5 of 6 Systemic Sclerosis Patients Receiving Standard Lymphodepletion

You may also like

Crypto prices